Agile Therapeutics, Inc. (AGRX)
AGRX Price and Sentiment
AGRX Latest news
Agile Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on Tuesday, November 2, 20212021-10-22 08:01
Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
Agile Therapeutics continues to trade under intense selling pressure. This selling amplified after the company announced a sizeable offering.
If you're making a penny stocks watchlist right now, check these three small-caps out The post Top Penny Stocks to Watch Making Big Moves Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The stock price of Agile Therapeutics Inc (NASDAQ: AGRX) fell over 20% this past week. This is why it happened.
Looking for biotech penny stocks to watch on Reddit? Check these four out for your list The post Best Biotech Penny Stocks on Reddit to Buy Now?
Agile Therapeutics Applauds Congressional Chairs' Letter to Biden Administration Requesting Enforcement of Contraceptive Access Under Affordable Care Act2021-10-12 08:01
PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today applauded House Congressional Committee leaders in urging the Secretaries of U.S. Departments of Health and Human Services (HHS), Treasury, and Labor to enforce the law regarding women's access to contraceptive methods as dictated by the Affordable Care Act (ACA).
PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Josephine Torrente has been appointed to the Company's board of directors, as a Class II director, effective as of October 7, 2021. Ms. Torrente will serve on Agile's Science and Technology Committee and Nominating and Corporate Governance Committee.
Agile Therapeutics Announces Pricing of $22,666,650 Underwritten Public Offering of Common Stock and Warrants2021-10-08 08:30
PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the pricing of its underwritten public offering of 26,666,648 shares of its common stock and warrants to purchase 13,333,324 shares of its common stock at a combined offering price to the public of $0.85 per one share of common stock and one-half of a warrant to purchase one share of common stock. The warrants have an exercise price of $0.85 per share of common stock, are exercisable immediately, and will expire five years from the date of issuance. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $22,666,650. All securities in the offering will be sold by Agile Therapeutics.
PRINCETON, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Largest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021 Largest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021